Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.30M$4.30Mderived+154.4% vs Q4 2023 Net Income-$35.14M-$35.14MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$38,029,000N/M Operating Cash Flowderived-$7,438,000N/M Margins · derivedOperating margin-884.0%−562.9 pt vs Q4 2023
Net margin-816.7%−533.2 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end